

Robin J Shattock

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4758647/publications.pdf>

Version: 2024-02-01

137
papers

6,896
citations

71061

41
h-index

71651

76
g-index

147
all docs

147
docs citations

147
times ranked

7839
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibiting sexual transmission of HIV-1 infection. <i>Nature Reviews Microbiology</i> , 2003, 1, 25-34.	13.6	468
2	Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. <i>Nature Communications</i> , 2020, 11, 3523.	5.8	357
3	Parameters of Human Immunodeficiency Virus Infection of Human Cervical Tissue and Inhibition by Vaginal Virucides. <i>Journal of Virology</i> , 2000, 74, 5577-5586.	1.5	307
4	Generation of Transmitted/Founder HIV-1 Infectious Molecular Clones and Characterization of Their Replication Capacity in CD4 T Lymphocytes and Monocyte-Derived Macrophages. <i>Journal of Virology</i> , 2012, 86, 2715-2728.	1.5	291
5	In Vitro and In Vivo. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 39, 1-8.	0.9	245
6	Blockade of Attachment and Fusion Receptors Inhibits HIV-1 Infection of Human Cervical Tissue. <i>Journal of Experimental Medicine</i> , 2004, 199, 1065-1075.	4.2	217
7	Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9. <i>Journal of General Virology</i> , 2015, 96, 2381-2393.	1.3	168
8	Biological and Technical Variables Affecting Immunoassay Recovery of Cytokines from Human Serum and Simulated Vaginal Fluid: A Multicenter Study. <i>Analytical Chemistry</i> , 2008, 80, 4741-4751.	3.2	161
9	Prevention of SIV Rectal Transmission and Priming of T Cell Responses in Macaques after Local Pre-exposure Application of Tenofovir Gel. <i>PLoS Medicine</i> , 2008, 5, e157.	3.9	159
10	Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. <i>PLoS Pathogens</i> , 2015, 11, e1005042.	2.1	145
11	Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA. <i>Gene Therapy</i> , 2019, 26, 363-372.	2.3	137
12	Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 seroprevalence survey. <i>Thorax</i> , 2020, 75, 1082-1088.	2.7	133
13	Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 1091-1100.	4.6	120
14	Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence. <i>Nature Communications</i> , 2019, 10, 2355.	5.8	116
15	Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice. <i>Nature Communications</i> , 2021, 12, 2893.	5.8	104
16	Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 Agonist, Promotes Potent Systemic and Mucosal Responses to Intranasal Immunization with HIVgp140. <i>PLoS ONE</i> , 2012, 7, e41144.	1.1	96
17	The Nucleoside Reverse Transcriptase Inhibitor UC-781 Inhibits Human Immunodeficiency Virus Type 1 Infection of Human Cervical Tissue and Dissemination by Migratory Cells. <i>Journal of Virology</i> , 2005, 79, 11179-11186.	1.5	93
18	HIV-1 infection of human penile explant tissue and protection by candidate microbicides. <i>Aids</i> , 2009, 23, 319-328.	1.0	93

#	ARTICLE	IF	CITATIONS
19	Big Is Beautiful: Enhanced saRNA Delivery and Immunogenicity by a Higher Molecular Weight, Bioreducible, Cationic Polymer. <i>ACS Nano</i> , 2020, 14, 5711-5727.	7.3	92
20	Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial. <i>EClinicalMedicine</i> , 2022, 44, 101262.	3.2	87
21	Emerging Technologies for Low-Cost, Rapid Vaccine Manufacture. <i>Biotechnology Journal</i> , 2019, 14, e1800376.	1.8	86
22	Turning the Tide Against HIV. <i>Science</i> , 2011, 333, 42-43.	6.0	84
23	Novel Approaches to Vaginal Delivery and Safety of Microbicides: Biopharmaceuticals, Nanoparticles, and Vaccines. <i>Antiviral Research</i> , 2010, 88, S55-S66.	1.9	80
24	Microneedle mediated intradermal delivery of adjuvanted recombinant HIV-1 CN54gp140 effectively primes mucosal boost inoculations. <i>Journal of Controlled Release</i> , 2012, 162, 529-537.	4.8	80
25	Reverse Transcriptase Inhibitors as Potential Colorectal Microbicides. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1797-1807.	1.4	77
26	Resources, Production Scales and Time Required for Producing RNA Vaccines for the Global Pandemic Demand. <i>Vaccines</i> , 2021, 9, 3.	2.1	74
27	Critical issues in mucosal immunity for HIV-1 vaccine development. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 122, 3-9.	1.5	68
28	Sustained Release of the CCR5 Inhibitors CMPD167 and Maraviroc from Vaginal Rings in Rhesus Macaques. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2251-2258.	1.4	60
29	SARS-CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (React 2): diagnostic accuracy study. <i>BMJ</i> , The, 2021, 372, n423.	3.0	56
30	RNA Vaccines: A Suitable Platform for Tackling Emerging Pandemics?. <i>Frontiers in Immunology</i> , 2020, 11, 608460.	2.2	54
31	Improving Defences at the Portal of HIV Entry: Mucosal and Innate Immunity. <i>PLoS Medicine</i> , 2008, 5, e81.	3.9	53
32	Rapid development and deployment of high-volume vaccines for pandemic response. <i>Journal of Advanced Manufacturing and Processing</i> , 2020, 2, e10060.	1.4	53
33	Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines. <i>Journal of Controlled Release</i> , 2021, 338, 201-210.	4.8	53
34	Phase I Randomised Clinical Trial of an HIV-1CN54, Clade C, Trimeric Envelope Vaccine Candidate Delivered Vaginally. <i>PLoS ONE</i> , 2011, 6, e25165.	1.1	52
35	Highly conserved HIV-1 gp120 glycans proximal to CD4-binding region affect viral infectivity and neutralizing antibody induction. <i>Virology</i> , 2012, 423, 97-106.	1.1	51
36	One Size Does Not Fit All: The Effect of Chain Length and Charge Density of Poly(ethylene imine) Based Copolymers on Delivery of pDNA, mRNA, and RepRNA Polyplexes. <i>Biomacromolecules</i> , 2018, 19, 2870-2879.	2.6	51

#	ARTICLE	IF	CITATIONS
37	Evaluation of TLR Agonists as Potential Mucosal Adjuvants for HIV gp140 and Tetanus Toxoid in Mice. PLoS ONE, 2012, 7, e50529.	1.1	51
38	Immune Activation in the Female Genital Tract: Expression Profiles of Soluble Proteins in Women at High Risk for HIV Infection. PLoS ONE, 2016, 11, e0143109.	1.1	51
39	Multisite Comparison of Anti-Human Immunodeficiency Virus Microbicide Activity in Explant Assays Using a Novel Endpoint Analysis. Journal of Clinical Microbiology, 2009, 47, 3530-3539.	1.8	50
40	Rational Design of DNA-Expressed Stabilized Native-Like HIV-1 Envelope Trimers. Cell Reports, 2018, 24, 3324-3338.e5.	2.9	49
41	Innate activation of human primary epithelial cells broadens the host response to Mycobacterium tuberculosis in the airways. PLoS Pathogens, 2017, 13, e1006577.	2.1	48
42	Microbicides "aids to safer sex. Lancet, The, 2004, 363, 1002-1003.	6.3	46
43	Neutralizing IgG at the Portal of Infection Mediates Protection against Vaginal Simian/Human Immunodeficiency Virus Challenge. Journal of Virology, 2013, 87, 11604-11616.	1.5	44
44	The Skin You Are In: Design-of-Experiments Optimization of Lipid Nanoparticle Self-Amplifying RNA Formulations in Human Skin Explants. ACS Nano, 2019, 13, 5920-5930.	7.3	44
45	The complex challenges of HIV vaccine development require renewed and expanded global commitment. Lancet, The, 2020, 395, 384-388.	6.3	44
46	CCL19 and CCL28 Augment Mucosal and Systemic Immune Responses to HIV-1 gp140 by Mobilizing Responsive Immunocytes into Secondary Lymph Nodes and Mucosal Tissue. Journal of Immunology, 2013, 191, 1935-1947.	0.4	43
47	The synergistic effects of combining TLR ligand based adjuvants on the cytokine response are dependent upon p38/JNK signalling. Cytokine, 2017, 99, 287-296.	1.4	42
48	In vitro models of mucosal HIV transmission. Nature Medicine, 2000, 6, 607-607.	15.2	41
49	Capacity for Infectious HIV-1 Virion Capture Differs by Envelope Antibody Specificity. Journal of Virology, 2014, 88, 5165-5170.	1.5	41
50	Rice endosperm is cost-effective for the production of recombinant griffithsin with potent activity against HIV. Plant Biotechnology Journal, 2016, 14, 1427-1437.	4.1	40
51	Innate Inhibiting Proteins Enhance Expression and Immunogenicity of Self-Amplifying RNA. Molecular Therapy, 2021, 29, 1174-1185.	3.7	40
52	Antibody responses after intravaginal immunisation with trimeric HIV-1CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation. Vaccine, 2011, 29, 1421-1430.	1.7	39
53	Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen. Vaccine, 2011, 29, 1258-1269.	1.7	37
54	Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study. PLoS ONE, 2016, 11, e0152038.	1.1	37

#	ARTICLE	IF	CITATIONS
55	Isolation and Characterization of Antigen-Specific Plasmablasts Using a Novel Flow Cytometry-Based Ig Capture Assay. <i>Journal of Immunology</i> , 2017, 199, 4180-4188.	0.4	37
56	HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial. <i>PLoS ONE</i> , 2015, 10, e0131748.	1.1	37
57	Pulmonary delivery of DNA vaccine constructs using deacylated PEI elicits immune responses and protects against viral challenge infection. <i>Journal of Controlled Release</i> , 2013, 170, 452-459.	4.8	36
58	Quality by design modelling to support rapid RNA vaccine production against emerging infectious diseases. <i>Npj Vaccines</i> , 2021, 6, 65.	2.9	36
59	Glucopyranosyl Lipid A Adjuvant Significantly Enhances HIV Specific T and B Cell Responses Elicited by a DNA-MVA-Protein Vaccine Regimen. <i>PLoS ONE</i> , 2014, 9, e84707.	1.1	36
60	A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes. <i>Frontiers in Immunology</i> , 2017, 8, 149.	2.2	35
61	Thymic stromal lymphopoietin (TSLP) acts as a potent mucosal adjuvant for HIV gp140 vaccination in mice. <i>European Journal of Immunology</i> , 2012, 42, 353-363.	1.6	34
62	MiniCD4 Microbicide Prevents HIV Infection of Human Mucosal Explants and Vaginal Transmission of SHIV162P3 in Cynomolgus Macaques. <i>PLoS Pathogens</i> , 2012, 8, e1003071.	2.1	32
63	Enhanced Immunogenicity of an HIV-1 DNA Vaccine Delivered with Electroporation via Combined Intramuscular and Intradermal Routes. <i>Journal of Virology</i> , 2014, 88, 6959-6969.	1.5	32
64	Structural Components for Amplification of Positive and Negative Strand VEEV Splitsicons. <i>Frontiers in Molecular Biosciences</i> , 2018, 5, 71.	1.6	31
65	Effects of cationic adjuvant formulation particle type, fluidity and immunomodulators on delivery and immunogenicity of saRNA. <i>Journal of Controlled Release</i> , 2019, 304, 65-74.	4.8	30
66	Mannosylated Poly(ethylene imine) Copolymers Enhance saRNA Uptake and Expression in Human Skin Explants. <i>Biomacromolecules</i> , 2020, 21, 2482-2492.	2.6	30
67	Knowledge, Attitudes, and Practices Regarding COVID-19 among Healthcare Workers in Uganda: A Cross-Sectional Survey. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 7004.	1.2	30
68	Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies. <i>Journal of Virology</i> , 2017, 91, .	1.5	29
69	Unexpected synergistic HIV neutralization by a triple microbicide produced in rice endosperm. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E7854-E7862.	3.3	28
70	Effect of complexing lipids on cellular uptake and expression of messenger RNA in human skin explants. <i>Journal of Controlled Release</i> , 2021, 330, 1250-1261.	4.8	28
71	Intravaginal immunization using the recombinant HIV-1 clade-C trimeric envelope glycoprotein CN54gp140 formulated within lyophilized solid dosage forms. <i>Vaccine</i> , 2011, 29, 4512-4520.	1.7	27
72	TLR4 and TLR7/8 Adjuvant Combinations Generate Different Vaccine Antigen-Specific Immune Outcomes in Minipigs when Administered via the ID or IN Routes. <i>PLoS ONE</i> , 2016, 11, e0148984.	1.1	27

#	ARTICLE	IF	CITATIONS
73	Aggregate complexes of HIV-1 induced by multimeric antibodies. <i>Retrovirology</i> , 2014, 11, 78.	0.9	26
74	Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 252-257.	0.9	25
75	Flow virometry analysis of envelope glycoprotein conformations on individual HIV virions. <i>Scientific Reports</i> , 2017, 7, 948.	1.6	25
76	Identification of potential biomarkers of vaccine inflammation in mice. <i>ELife</i> , 2019, 8, .	2.8	25
77	Mucosal Tissue Tropism and Dissemination of HIV-1 Subtype B Acute Envelope-Expressing Chimeric Virus. <i>Journal of Virology</i> , 2013, 87, 890-899.	1.5	23
78	Polymeric penetration enhancers promote humoral immune responses to mucosal vaccines. <i>Journal of Controlled Release</i> , 2014, 183, 43-50.	4.8	23
79	Tetherin restricts HSV-2 release and is counteracted by multiple viral glycoproteins. <i>Virology</i> , 2015, 475, 96-109.	1.1	23
80	Expression Profile of Human Fc Receptors in Mucosal Tissue: Implications for Antibody-Dependent Cellular Effector Functions Targeting HIV-1 Transmission. <i>PLoS ONE</i> , 2016, 11, e0154656.	1.1	23
81	Macrophages are the major target cell for HIV infection in long-term bone marrow culture and demonstrate dual susceptibility to lymphocytotropic and monocytotropic strains of HIV-1. <i>British Journal of Haematology</i> , 1996, 93, 30-37.	1.2	22
82	The Multifaceted Nature of Immunoglobulin A and Its Complex Role in HIV. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 727-738.	0.5	22
83	Potential Use of Protease Inhibitors as Vaginal and Colorectal Microbicides. <i>Current HIV Research</i> , 2012, 10, 42-52.	0.2	20
84	Intramuscular Immunisation with Chlamydial Proteins Induces Chlamydia trachomatis Specific Ocular Antibodies. <i>PLoS ONE</i> , 2015, 10, e0141209.	1.1	20
85	A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine Regimens. <i>Frontiers in Immunology</i> , 2017, 8, 595.	2.2	20
86	The <i>In Vitro</i> , <i>Ex Vivo</i> , and <i>In Vivo</i> Effect of Polymer Hydrophobicity on Charge-Reversible Vectors for Self-Amplifying RNA. <i>Biomacromolecules</i> , 2020, 21, 3242-3253.	2.6	20
87	A "Prime-Pull" Vaccine Strategy Has a Modest Effect on Local and Systemic Antibody Responses to HIV gp140 in Mice. <i>PLoS ONE</i> , 2013, 8, e80559.	1.1	19
88	Mucosal Application of gp140 Encoding DNA Polyplexes to Different Tissues Results in Altered Immunological Outcomes in Mice. <i>PLoS ONE</i> , 2013, 8, e67412.	1.1	19
89	Intravaginal immunisation using a novel antigen-releasing ring device elicits robust vaccine antigen-specific systemic and mucosal humoral immune responses. <i>Journal of Controlled Release</i> , 2017, 249, 74-83.	4.8	18
90	Molecular Signatures of a TLR4 Agonist-Adjuvanted HIV-1 Vaccine Candidate in Humans. <i>Frontiers in Immunology</i> , 2018, 9, 301.	2.2	18

#	ARTICLE	IF	CITATIONS
91	Willingness to participate in COVID-19 vaccine trials; a survey among a population of healthcare workers in Uganda. <i>PLoS ONE</i> , 2021, 16, e0251992.	1.1	18
92	A heterogeneous human immunodeficiency virus-like particle (VLP) formulation produced by a novel vector system. <i>Npj Vaccines</i> , 2018, 3, 2.	2.9	17
93	Candidate Microbicides and Their Mechanisms of Action. <i>Current Topics in Microbiology and Immunology</i> , 2013, 383, 1-25.	0.7	16
94	Discrete partitioning of HIV-1 Env forms revealed by viral capture. <i>Retrovirology</i> , 2015, 12, 81.	0.9	16
95	Evaluation of mucosal adjuvants and immunization routes for the induction of systemic and mucosal humoral immune responses in macaques. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 2913-2922.	1.4	16
96	HIV-1 Expressing the Envelopes of Transmitted/Founder or Control/Reference Viruses Have Similar Infection Patterns of CD4 T-Cells in Human Cervical Tissue Ex Vivo. <i>PLoS ONE</i> , 2012, 7, e50839.	1.1	15
97	Ornithine-derived oligomers and dendrimers for <i>in vitro</i> delivery of DNA and <i>ex vivo</i> transfection of skin cells <i>via</i> saRNA. <i>Journal of Materials Chemistry B</i> , 2020, 8, 4940-4949.	2.9	15
98	Dynamic electrophoretic fingerprinting of the HIV-1 envelope glycoprotein. <i>Retrovirology</i> , 2013, 10, 33.	0.9	14
99	Lactobacillus-Depleted Vaginal Microbiota in Pregnant Women Living With HIV-1 Infection Are Associated With Increased Local Inflammation and Preterm Birth. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 596917.	1.8	14
100	Presentation of antigen on extracellular vesicles using transmembrane domains from viral glycoproteins for enhanced immunogenicity. <i>Journal of Extracellular Vesicles</i> , 2022, 11, e12199.	5.5	14
101	Immunogenicity of stabilized HIV-1 Env trimers delivered by self-amplifying mRNA. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 25, 483-493.	2.3	13
102	Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates. <i>Journal of Virology</i> , 2016, 90, 5315-5328.	1.5	12
103	A targeted reactivation of latent HIV-1 using an activator vector in patient samples from acute infection. <i>EBioMedicine</i> , 2020, 59, 102853.	2.7	12
104	A Novel Strategy for Inducing Enhanced Mucosal HIV-1 Antibody Responses in an Anti-Inflammatory Environment. <i>PLoS ONE</i> , 2011, 6, e15861.	1.1	11
105	The Safety and Immunogenicity of GTUÂ®MultiHIV DNA Vaccine Delivered by Transcutaneous and Intramuscular Injection With or Without Electroporation in HIV-1 Positive Subjects on Suppressive ART. <i>Frontiers in Immunology</i> , 2019, 10, 2911.	2.2	11
106	Short Communication: Limited Anti-HIV-1 Activity of Maraviroc in Mucosal Tissues. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 334-338.	0.5	10
107	Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP). <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2129-2136.	1.3	10
108	Induction of innate cytokine responses by respiratory mucosal challenge with R848 in zebrafish, mice, and humans. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 342-345.e7.	1.5	8

#	ARTICLE	IF	CITATIONS
109	Chemokine-Adjuvanted Plasmid DNA Induces Homing of Antigen-Specific and Non-Antigen-Specific B and T Cells to the Intestinal and Genital Mucosae. <i>Journal of Immunology</i> , 2020, 204, 903-913.	0.4	8
110	An improved synthesis of poly(amidoamine)s for complexation with self-amplifying RNA and effective transfection. <i>Polymer Chemistry</i> , 2020, 11, 5861-5869.	1.9	8
111	Precisely targeted gene delivery in human skin using supramolecular cationic glycopolymers. <i>Polymer Chemistry</i> , 2020, 11, 3768-3774.	1.9	8
112	Interplay of diverse adjuvants and nanoparticle presentation of native-like HIV-1 envelope trimers. <i>Npj Vaccines</i> , 2021, 6, 103.	2.9	8
113	Envelope-Specific Recognition Patterns of HIV Vaccine-Induced IgG Antibodies Are Linked to Immunogen Structure and Sequence. <i>Frontiers in Immunology</i> , 2019, 10, 717.	2.2	7
114	Early Colorectal Responses to HIV-1 and Modulation by Antiretroviral Drugs. <i>Vaccines</i> , 2021, 9, 231.	2.1	7
115	A self-amplifying RNA vaccine protects against SARS-CoV-2 (D614G) and Alpha variant of concern (B.1.1.7) in a transmission-challenge hamster model. <i>Vaccine</i> , 2022, 40, 2848-2855.	1.7	7
116	Infection of ectocervical tissue and universal targeting of T-cells mediated by primary non-macrophage-tropic and highly macrophage-tropic HIV-1 R5 envelopes. <i>Retrovirology</i> , 2015, 12, 48.	0.9	6
117	HIV-1 CNS in vitro infectivity models based on clinical CSF samples. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 235-243.	1.3	6
118	Plasmid DNA Vaccine Co-Immunisation Modulates Cellular and Humoral Immune Responses Induced by Intranasal Inoculation in Mice. <i>PLoS ONE</i> , 2015, 10, e0141557.	1.1	6
119	Antigenicity and immunogenicity of HIV-1 gp140 with different combinations of glycan mutation and V1/V2 region or V3 crown deletion. <i>Vaccine</i> , 2019, 37, 7501-7508.	1.7	5
120	The entry inhibitor DS003 (BMS-599793): a BMS-806 analogue, provides superior activity as a pre-exposure prophylaxis candidate. <i>Aids</i> , 2021, 35, 1907-1917.	1.0	5
121	CD71 targeting boosts immunogenicity of sublingually delivered influenza haemagglutinin antigen and protects against viral challenge in mice. <i>Journal of Controlled Release</i> , 2016, 232, 75-82.	4.8	4
122	Infection of rhesus macaques with a pool of simian immunodeficiency virus with the envelope genes from acute HIV-1 infections. <i>AIDS Research and Therapy</i> , 2016, 13, 41.	0.7	3
123	Localized cyclical variations in immunoproteins in the female genital tract and the implications on the design and assessment of mucosal infection and therapies. <i>American Journal of Reproductive Immunology</i> , 2018, 79, e12801.	1.2	3
124	Blocking T cell egress with FTY720 extends DNA vaccine expression but reduces immunogenicity. <i>Immunology</i> , 2022, 165, 301-311.	2.0	2
125	Ex Vivo Evaluation of Mucosal Responses to Vaccination with ALVAC and AIDSVAX of Non-Human Primates. <i>Vaccines</i> , 2022, 10, 187.	2.1	2
126	Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimers. <i>Npj Vaccines</i> , 2022, 7, 44.	2.9	2

#	ARTICLE	IF	CITATIONS
127	Knowing Whom We Are trying to Protect: An Assessment of HIV Risk in South African Adolescent Females. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A131-A131.	0.5	1
128	Isolating Pathogen-Specific Human Monoclonal Antibodies (hmAbs) Using Bacterial Whole Cells as Molecular Probes. <i>Methods in Molecular Biology</i> , 2021, 2183, 9-18.	0.4	1
129	Exploring Innovative Approaches to the Formulation of Microbicides to Boost Antiretroviral Drug Delivery and Activity at Mucosal Sites. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A150-A151.	0.5	0
130	HIV-1 Transmission Blocking Microbicides. , 2014, , 1-8.		0
131	Combinations of TLR4 and TLR7/8 Adjuvants Administered via the ID or IN Routes Generate Different Vaccine Antigen-specific Immune Outcomes in Minipigs. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A194-A195.	0.5	0
132	Intradermal HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A31-A32.	0.5	0
133	Functional Assessment of Antibody Activity in Mucosal Tissue Explant and Cellular Inhibition Assays. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A230-A230.	0.5	0
134	A Phase I Clinical Trial with a Novel gp41 HIV Vaccine (EN41-FPA2) in Healthy Female Volunteers: A Mucosal Prime and Intramuscular Boost Regimen. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A187-A188.	0.5	0
135	HIV vaccine research in Canada. <i>AIDS Research and Therapy</i> , 2017, 14, 54.	0.7	0
136	HIV-1 Transmission Blocking Microbicides. , 2018, , 913-919.		0
137	Use of Chlamydial Elementary Bodies as Probes to Isolate Pathogen-Specific Human Monoclonal Antibodies. <i>Methods in Molecular Biology</i> , 2021, 2183, 19-28.	0.4	0